To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
What Do You Think?
How would you vote?
Referandom Vote
Vote to see the result.
How Congress Voted
PendingWhat Happened in Congress?
Not yet voted on the floor.
Where the Bill Stands
- Introduced, done
- Committee, current stage
- Floor Vote, not yet
- Outcome, not yet
Sponsors
Timeline
- Library of CongressIntroduced in House
- House floor actionsReferred to the House Committee on Energy and Commerce.
- Introduced
- Committee

Comments
Comments with insults, hate speech or personal information are removed.